west virginia semaglutide side effect lawsuit The FDA has issued a warning to Novo Nordisk over its alleged failure to report adverse effects, including death, in patients who took its GLP-1 medications, popularly known as Ozempic and semaglutide side effect class action

The future is bright with peptides

Regular follow-up with a registered dietitian experienced in obesity medicine can provide personalized guidance and troubleshooting for patients struggling to maintain adequate protein intake while on GLP-1 therapy

The choice impacts load capacity, material efficiency, and total installed cost

Future research employing multiomics technologies will be essential to unravel the mechanisms underlying these interactions and to guide the development of individualised therapeutic strategies for obesity and T2D [82]

doi:10.4314/ovj.v7i1.6

About this article Cite this article Wolk, R., Massi, D